Next Article in Journal / Special Issue
Inter-Rater Reliability of Provider Interpretations of Irritable Bowel Syndrome Food and Symptom Journals
Previous Article in Journal / Special Issue
Gender and Weight Influence Quality of Life in Irritable Bowel Syndrome
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessFeature PaperReview
J. Clin. Med. 2017, 6(11), 104; doi:10.3390/jcm6110104

Adenosine A2B Receptors: An Optional Target for the Management of Irritable Bowel Syndrome with Diarrhea?

Institute of Medical Science, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki 216-8512, Japan
*
Author to whom correspondence should be addressed.
Received: 9 October 2017 / Revised: 31 October 2017 / Accepted: 2 November 2017 / Published: 3 November 2017
(This article belongs to the Special Issue Irritable Bowel Syndrome)
View Full-Text   |   Download PDF [212 KB, uploaded 4 November 2017]

Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, with the characteristic symptoms of chronic abdominal pain and altered bowel habits (diarrhea, constipation, or both). IBS is a highly prevalent condition, which negatively affects quality of life and is a significant burden on global healthcare costs. Although many pharmacological medicines have been proposed to treat IBS, including those targeting receptors, channels, and chemical mediators related to visceral hypersensitivity, successful pharmacotherapy for the disease has not been established. Visceral hypersensitivity plays an important role in IBS pathogenesis. Immune activation is observed in diarrhea-predominant patients with IBS and contributes to the development of visceral hypersensitivity. Adenosine is a chemical mediator that regulates many physiological processes, including inflammation and nociception. Among its receptors, the adenosine A2B receptor regulates intestinal secretion, motor function, and the immune response. We recently demonstrated that the adenosine A2B receptor is involved in visceral hypersensitivity in animal models of IBS. In this review, we discuss the possibility of the adenosine A2B receptor as a novel therapeutic target for IBS. View Full-Text
Keywords: adenosine A2B receptor; irritable bowel syndrome; visceral hypersensitivity; diarrhea; abdominal pain; immune response adenosine A2B receptor; irritable bowel syndrome; visceral hypersensitivity; diarrhea; abdominal pain; immune response
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Asano, T.; Takenaga, M. Adenosine A2B Receptors: An Optional Target for the Management of Irritable Bowel Syndrome with Diarrhea? J. Clin. Med. 2017, 6, 104.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top